Breast reconstruction and radiotherapy
a literature review
Keywords:
breast cancer, mammaplasty, breast implants, radiotherapy, adjuvant, surgical flapsAbstract
Breast cancer is the most common malignancy in women worldwide. After mastectomy, many women wish to reconstruct the affected breast and immediate breast reconstruction has been proven oncologically safe compared to mastectomy only. In addition, indications for post-mastectomy radiotherapy (PMRT) sessions are becoming more frequent, due to their relationship with reduced mortality and locoregional recurrence. For this reason, many women who opted for immediate reconstruction underwent radiotherapy with implants or expanders. The objective of this study was to compare the outcome of patients with breast cancer undergoing adjuvant radiotherapy after breast reconstruction with an implant or expander with that of patients who did not need irradiation. A literature review was carried out on the CAPES Journal Portal. The studies are unanimous when it comes to the increased risk of complications between control groups and patients who have undergone PMRT. Reconstruction failure rates were lower and the esthetic results were better in surgeries with implants compared with tissue expanders. Autologous surgeries are apparently safe and should be considered in the context of PMRT. This review did not find sufficient scientific evidence to determine the best technique and the best period for radiotherapy in PMRT indications. The choice of the surgical technique and the time of radiotherapy must be at the discretion of the surgeon and multidisciplinary team of each service, always in a shared decision with the patient.
Downloads
References
Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa 2020: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2019.
Global Cancer Observatory. International Agency for Research on Cancer. Available from: https://gco.iarc.fr/.
de Paula LB, Santos RS, Lima PS, de Paula NM, Reis AAS. Os genes BRCA1 e BRCA2 e suas relações genéticas na predisposição aos carcinomas mamários hereditários e esporádicos. Revista EVS-Revista de Ciências Ambientais e Saúde. 2010;37(6). http://doi.org/10.18224/est.v37i6.1898
Prolla CMD, Silva PS, Netto CBO, Goldim JR, Ashton-Prolla
P. Conocimiento del cáncer de mama y cáncer de mama hereditário em el personal de enfermería de un hospital público. Rev Latino-Am Enfermagem. 2015;23(1):90-7. https://doi.org/10.1590/0104-1169.0185.2529
Ferraz VEF, Cury NM. Como o ginecologista pode orientar mulheres com antecedentes familiares de câncer? Rev Bras Ginecol Obstet. 2014;36(8):335-9. https://doi.org/10.1590/SO100-720320140005104
Corso G, Montagna G, Figueiredo J, La Vecchia C, Romario UF, Fernandes MS, et al. Hereditary gastric and breast câncer syndromes related to CDH1 germline mutation: a multidisciplinary clinical review. Cancers (Basel). 2020;12(6):1598. https://doi.org/10.3390/cancers12061598
Berliner JL, Fay AM, Cummings SA, Burnett B, Tillmanns T. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. J Genet Couns. 2013;22(2):155-63. https://doi.org/10.1007/s10897-012-9547-1
Silva FC, Lisboa BC, Figueiredo MC, Torrezan GT, Santos EM, Krepischi AC, et al. Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients. BMC Med Genet. 2014;15:55. https://doi.org/10.1186/1471-2350-15-55
Torrezan GT, de Almeida FGSR, Figueiredo MCP, Barros BDF, de Paula CAA, Valieris R, et al. Complex landscape of germline variants in Brazilian patients with hereditary and early onset breast cancer. Front Genet. 2018;9:161. https://doi.org/10.3389/fgene.2018.00161
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Genetic/familial high-risk assessment: breast and ovarian. NCCN Guidelines Version 3.2019; January 18, 2019. Available from: https://www2.tri-kobe.org/nccn/guideline/gynecological/english/genetic_ familial.pdf.
Palmero EI, Alemar B, Schüler-Faccini L, Hainaut P, Moreira-Filho CA, Ewald IP, et al. Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil. Genet Mol Biol. 2016;39(2):210-22. https://doi.org/10.1590/1678-4685-GMB-2014-0363
Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117-30. https://doi.org/10.1086/375033
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66-71. https://doi.org/10.1126/science.7545954
Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265(5181):2088-90. https://doi.org/10.1126/science.8091231
Lee A, Moon BI, Kim TH. BRCA1/BRCA2 pathogenic variant breast cancer: treatment and prevention strategies. Ann Lab Med. 2020;40(2):114-21. https://doi.org/10.3343/alm.2020.40.2.114
Ashton-Prolla P, Vargas FR. Prevalence and impact of founder mutations in hereditary breast cancer in Latin America. Genet Mol Biol. 2014;37(1 suppl 1):234-40. https://doi.org/10.1590/S1415-47572014000200009
Teugels E, Brakeleer S, Goelen G, Lissens W, Sermijn E, Grève J. De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes. Hum Mutat. 2005;26(3):284. https://doi.org/10.1002/humu.9366
Peixoto A, Santos C, Rocha P, Pinheiro M, Príncipe S, Pereira D, et al. The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. Breast Cancer Res Treat. 2009;114(1):31-8. https://doi.org/10.1007/s10549-008-9978-4
Palmero EI, Carraro DM, Alemar B, Moreira MAM, Ribeiro-Dos-Santos Â, Abe-Sandes K, et al. The germline mutational landscape of BRCA1 and BRCA2 in Brazil. Sci Rep. 2018;8(1):9188. https://doi.org/10.1038/s41598-018-27315-2
Li FP, Fraumeni Jr JF. Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med. 1969;71(4):747-52. https://doi.org/10.7326/0003-4819-71-4-747
Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, Le Clavez-Kelm F, et al. Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat. 2010;31(2):143-50. https://doi.org/10.1002/humu.21151
Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, et al. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int. 2015;2015:341723. https://doi.org/10.1155/2015/341723
Reis-Filho J, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378(9805):1812-23. https://doi.org/10.1016/S0140-6736(11)61539-0
Godet I, Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther. 2017;4(1). https://doi.org/10.15761%2FICST.1000228
Coelho AS, Santos MAS, Caetano RI, Piovesan CF, Fiuza L, Machado RLD, et al. Predisposição hereditária ao câncer de mama e sua relação com os genes BRCA1 e BRCA2: revisão da literatura. RBAC. 2018;50(1):17-21. https://doi.org/10.21877/2448-3877.201800615
Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25(43):5846-53. https://doi.org/10.1038/sj.onc.1209876
Bayraktar S, Glück S. Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Res Treat. 2012;135(2):355-66. https://doi.org/10.1007/s10549-012-2158-6
Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26(7):1291-9. https://doi.org/10.1093%2Fannonc%2Fmdv022
Lee TC, Reyna C, Shaughnessy E, Lewis JD. Screening of populations at high risk for breast cancer. J Surg Oncol. 2019;120(5):820-30. https://doi.org/10.1002/jso.25611
Urban LABD, Chala LF, Bauab SP, Schaefer MB, Santos RP, Maranhão NMA, et al. Recomendações do Colégio Brasileiro de Radiologia e Diagnóstico por Imagem, da Sociedade Brasileira de Mastologia e da Federação Brasileira das Associações de Ginecologia e Obstetrícia para o rastreamento do câncer de mama. Radiol Bras. 2017;50(4):244-9. http://doi.org/10.1590/0100-3984.2017-0069
Thuler LC. Considerações sobre a prevenção do câncer de mama feminino. Rev Bras Cancerol. 2003;49(4):227-38. https://doi.org/10.32635/2176-9745.RBC.2003v49n4.2076
Peixoto A, Santos C, Rocha P, Pinheiro M, Príncipe S, Pereira D, et al. The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. Breast Cancer Res Treat. 2009;114(1):31-8. https://doi.org/10.1007/s10549-008-9978-4
Palmero EI, Carraro DM, Alemar B, Moreira MAM, Ribeiro-Dos-Santos Â, Abe-Sandes K, et al. The germline mutational landscape of BRCA1 and BRCA2 in Brazil. Sci Rep. 2018;8(1):9188. https://doi.org/10.1038/s41598-018-27315-2
Li FP, Fraumeni Jr JF. Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med. 1969;71(4):747-52. https://doi.org/10.7326/0003-4819-71-4-747
Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, Le Clavez-Kelm F, et al. Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat. 2010;31(2):143-50. https://doi.org/10.1002/humu.21151
Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, et al. Hereditary ovarian cancer: not only BRCA 1 and 2 genes. Biomed Res Int. 2015;2015:341723. https://doi.org/10.1155/2015/341723
Reis-Filho J, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011;378(9805):1812-23. https://doi.org/10.1016/S0140-6736(11)61539-0
Godet I, Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr Cancer Sci Ther. 2017;4(1). https://doi.org/10.15761%2FICST.1000228
Coelho AS, Santos MAS, Caetano RI, Piovesan CF, Fiuza L, Machado RLD, et al. Predisposição hereditária ao câncer de mama e sua relação com os genes BRCA1 e BRCA2: revisão da literatura. RBAC. 2018;50(1):17-21. https://doi.org/10.21877/2448-3877.201800615
Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25(43):5846-53. https://doi.org/10.1038/sj.onc.1209876
Bayraktar S, Glück S. Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Res Treat. 2012;135(2):355-66. https://doi.org/10.1007/s10549-012-2158-6
Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26(7):1291-9. https://doi.org/10.1093%2Fannonc%2Fmdv022
Lee TC, Reyna C, Shaughnessy E, Lewis JD. Screening of populations at high risk for breast cancer. J Surg Oncol. 2019;120(5):820-30. https://doi.org/10.1002/jso.25611
Urban LABD, Chala LF, Bauab SP, Schaefer MB, Santos RP, Maranhão NMA, et al. Recomendações do Colégio Brasileiro de Radiologia e Diagnóstico por Imagem, da Sociedade Brasileira de Mastologia e da Federação Brasileira das Associações de Ginecologia e Obstetrícia para o rastreamento do câncer de mama. Radiol Bras. 2017;50(4):244-9. http://doi.org/10.1590/0100-3984.2017-0069
Thuler LC. Considerações sobre a prevenção do câncer de mama feminino. Rev Bras Cancerol. 2003;49(4):227-38. https://doi.org/10.32635/2176-9745.RBC.2003v49n4.2076
Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van’t Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2004;22(6):1055-62. https://doi.org/10.1200/JCO.2004.04.188.
Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. N Engl J Med. 2016;374(5):454-68. https://doi.org/10.1056/NEJMra1503523
Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159-64. https://doi.org/10.1056/NEJM200107193450301
Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. 2018;4(4):CD002748. https://doi.org/10.1002/14651858.CD002748.pub4
Evans DGR, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2013;140(1):135-42. https://doi.org/10.1007/s10549-013-2583-1
Heemskerk-Gerritsen BAM, Rookus MA, Aalfs CM, Ausems MGEM, Collée JM, Jansen L, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015;136(3):668-77. https://doi.org/10.1002/ijc.29032
Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226. https://doi.org/10.1136/bmj.g226
van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, van Asperen CJ, Rutgers EJT, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005;93(3):287-92. https://doi.org/10.1038/sj.bjc.6602703
Onitilo AA, Engel JM, Stankowski RV, Doi SAR. Survival comparisons for breast conserving surgery and mastectomy revisited: community experience and the role of radiation therapy. Clin Med Res. 2015;13(2):65-73. https://doi.org/10.3121/cmr.2014.1245
Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014;144(3):443-55. https://doi.org/10.1007/s10549-014-2890-1
Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000;18(19):3360-9. https://doi.org/10.1200/JCO.2000.18.19.3360
Pouptsis A, Swafe L, Patwardhan M, Stavraka C. Surgical and systemic treatment of hereditary breast cancer: a mini-review with a focus on BRCA1 and BRCA2 mutations. Front Oncol. 2020;10:553080. https://doi.org/10.3389/fonc.2020.553080
Nakonechny QB, Gilks CB. Ovarian cancer in hereditary cancer susceptibility syndromes. Surg Pathol Clin. 2016;9(2):189-99. https://doi.org/10.1016/j.path.2016.01.003
Kim SJ, Sota Y, Naoi Y, Honma K, Kagara N, Miyake T, et al. Determining homologous recombination deficiency scores with whole exome sequencing and their association with responses to neoadjuvant chemotherapy in breast cancer. Transl Oncol. 2021;14(2):100986. https://doi.org/10.1016/j.tranon.2020.100986
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Maria Luiza de Oliveira Almeida Bax, Matheus Assis dos Anjos Bastos Oliveira, Calliny Cristina Pimentel Alves, Clécio Ênio Murta de Lucena
This work is licensed under a Creative Commons Attribution 4.0 International License.
